<DOC>
	<DOCNO>NCT03084016</DOCNO>
	<brief_summary>This study aim assess feasibility capture data exhale breath compound acute asthma exacerbation . In addition assess feasibility study investigator collect data exploratory outcome include ability breath biomarkers distinguish control exacerbated state ability differentiate trigger exacerbation .</brief_summary>
	<brief_title>Asthma Breath Biomarker Assessment</brief_title>
	<detailed_description>This longitudinal observational study investigator assess ability capture information volatile organic compound exhale breath acute asthma exacerbation use two different approach : A ) Recruitment assessment patient secondary care acute exacerbation asthma ; patient re-assessed asthma stable control . B ) Recruitment clinically stable outpatient increase risk exacerbation virtue acute exacerbation within previous 12 month . Participants follow period 12 month ; assess event exacerbation ; re-assessed controlled .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Male female 2 . Aged 18 3 . Able provide inform consent 4 . A confirmed asthma diagnosis require treatment inhale bronchodilator therapy +/ inhale corticosteroid . 5 . Nonsmoker ( exsmoker 6 month le 10 pack year history ) . 6 . Current exacerbation exacerbation within previous 12 month . 7 . Within 24 hour present acute secondary care ( applicable current exacerbation ) 1 . Major chronic cardiorespiratory disease asthma 2 . Significant comorbid condition 3 . Receiving maintenance oral corticosteroid therapy immunosuppressant immunomodulatory therapy ( include biologics ) 4 . Pregnant 5 . Participating clinical trial investigational medicinal product ( CTIMP ) . 6 . Unable speak English .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>